A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells by Carmo, Catarina R. et al.
A Novel Requirement for Janus Kinases as Mediators of
Drug Resistance Induced by Fibroblast Growth Factor-2
in Human Cancer Cells
Catarina R. Carmo, Janet Lyons-Lewis, Michael J. Seckl, Ana P. Costa-Pereira*
Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Abstract
The development of resistance to chemotherapy is a major cause of cancer-related death. Elucidating the mechanisms of
drug resistance should thus lead to novel therapeutic strategies. Fibroblast growth factor (FGF)-2 signaling induces the
assembly of a multi-protein complex that provides tumor cells with the molecular machinery necessary for drug resistance.
This complex, which involves protein kinase C (PKC) e, v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) and p70 S6
kinase b (S6K2), enhances the selective translation of anti-apoptotic proteins such as B-cell leukaemia/lymphoma-2 (BCL-2)
and inhibitors of apoptosis protein (IAP) family members and these are able to protect multiple cancer cell types from
chemotherapy-induced cell death. The Janus kinases (JAKs) are most noted for their critical roles in mediating cytokine
signaling and immune responses. Here, we show that JAKs have novel functions that support their consideration as new
targets in therapies aimed at reducing drug resistance. As an example, we show that the Janus kinase TYK2 is
phosphorylated downstream of FGF-2 signaling and required for the full phosphorylation of extracellular signal-regulated
kinase (ERK) 1/2. Moreover, TYK2 is necessary for the induction of key anti-apoptotic proteins, such as BCL-2 and myeloid
cell leukemia sequence (MCL) 1, and for the promotion of cell survival upon FGF-2. Silencing JAK1, JAK2 or TYK2 using RNA
interference (RNAi) inhibits FGF2-mediated proliferation and results in the sensitization of tumor cells to chemotherapy-
induced killing. These effects are independent of activation of signal transducer and activator of transcription (STAT) 1,
STAT3 and STAT5A/B, the normal targets of JAK signaling. Instead, TYK2 associates with the other kinases previously
implicated in FGF-2-mediated drug resistance. In light of these findings we hypothesize that TYK2 and other JAKs are
important modulators of FGF-2-driven cell survival and that inhibitors of these kinases will likely improve the effectiveness
of other cancer therapies.
Citation: Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP (2011) A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by
Fibroblast Growth Factor-2 in Human Cancer Cells. PLoS ONE 6(5): e19861. doi:10.1371/journal.pone.0019861
Editor: Rakesh K. Srivastava, The University of Kansas Medical Center, United States of America
Received February 8, 2011; Accepted April 5, 2011; Published May 20, 2011
Copyright:  2011 Carmo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Cancer Treatment and Research Trust funded this work. MJS and JLL are also supported by a Department of Health funded Experimental Cancer
Medicine Centre Grant, and APC-P and MJS by Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: a.costa-pereira@imperial.ac.uk
Introduction
The development of drug resistance by tumor cells is responsible
for the poor overall survival seen with most cancer types [1].
Amongst the plethora of drug resistance mechanisms lies fibroblast
growth factor (FGF)-2 signaling. FGF-2 can provide cells with pro-
survivaland mitogenic signals, and confer broad-spectrum resistance
to chemotherapeutic drugs [2,3,4]. De-regulated FGF-2 signaling
hasbeen associatedwith avarietyofmalignanciesandelevatedlevels
of this molecule in patient’s serum were established as an
independent poor prognostic factor for lymphoma, lung cancer
and sarcoma patients [5,6,7]. In particular, FGF-2 was shown to
promote drug resistance of small cell lung cancer (SCLC) cells
through the formation of a multi-protein complex comprising
protein kinase C (PKC) e, v-raf murine sarcoma viral oncogene
homologB1(B-RAF)andp70S6kinaseb(S6K2).Thisdependedon
extracellular signal-regulated kinase (ERK) 1/2 activity [3,8,9]. The
formation of this complex led to translational up-regulation of key
anti-apoptotic proteins, which then conferred resistance to apoptosis
and allowed cells to survive when challenged with cytotoxic drugs.
Most cytokines and many growth factors signal via Janus kinases
(JAKs) and signal transducers and activators of transcription
(STATs) [10,11]. Constitutive STAT phosphorylation is charac-
teristic of a wide variety of human cancer cell lines and primary
tumors [12]. Overactivation of JAKs has also been implicated in
tumorigenesis [13]. The fact that JAKs and STATs are activated
by multiple mitogens has encouraged researchers to develop
strategies to target them in cancer treatments. There is limited,
somewhat confusing, evidence for JAK/STAT signaling down-
stream of FGF-2 and its relevance is unclear [14,15,16]. We and
others [17] have observed de-regulated JAK/STAT expression in
a variety of lung carcinoma and sarcoma cell lines. This and the
fact that patients with elevated FGF-2 in the serum have poorer
outcomes in the clinic led us to hypothesize that JAKs and/or
STATs played a role in FGF-2 signaling-mediated drug resistance
pathway(s). Here, we show that the Janus kinases JAK1, JAK2 and
TYK2, but not their main downstream effectors STAT1, STAT3
or STAT5A/B, are required for FGF-2-mediated chemoprotec-
tion in U2OS osteosarcoma cells. This, in turn, opens new
therapeutic avenues for cancers that are still difficult to control.
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FGF-2 protects osteosarcoma U2OS cells from cisplatin-
mediated cell death through a mechanism that involves
PKCe, B-RAF and S6K2 protein complexes
Since FGF-2 was shown to protect SCLC cells from cytotoxic
drug-induced cell death [4], we initially sought to extend this
observation to the distinct cancer cell type osteosarcoma U2OS
cells. These were treated with the clinically relevant drug cisplatin
in the presence and absence of FGF-2 (Fig. 1). The concentration
of growth factor used was determined using ERK1/2 phosphor-
ylation as a readout (Fig. S1). Cell death was assessed using the
WST-1 cell viability assay, which yielded identical results to those
obtained by cell counting with trypan blue (data not shown).
Overnight treatment with 60 mM cisplatin killed 50% of the cells
but pre-incubation with FGF-2 for 4 h prevented this, suggesting
that FGF-2 protected U2OS cells against cisplatin (Fig. 1A). The
WST-1 assay does not discriminate between apoptosis and
necrosis. Moreover, the rescue from cisplatin could be attributed
to proliferation, which was also induced by FGF-2, rather than
purely to inhibition of cell death. We therefore monitored in
parallel the induction of apoptosis using cleavage of caspase
substrates such as poly(ADP-ribose) polymerase (PARP) and lamin
B as read-outs (Fig. 1B and data not shown). In addition, cell
cycle analysis by flow cytometry was used to quantify loss of DNA
content, which can be used as another readout for apoptosis
(Fig. 1C). Overnight treatment with cisplatin induced apoptosis in
U2OS cells, which was manifested by the appearance of an
85 kDa PARP cleavage fragment (Fig. 1B) and an increase of the
sub-G1 cell population (Fig. 1C). These events were prevented by
pre-treating cells with FGF-2, which also reduced basal cell death
detected in untreated samples. The graphs represent the average
values obtained in three independent experiments. As observed for
SCLC cells [8], the reduction of cell death by FGF-2 could be
prevented by inhibition of mitogen-activated protein kinase kinase
(MEK)/ERK activity with a selective inhibitor (Fig. S2), whilst
inhibition of phosphatidylinositol 3-kinase (PI3K) and target of
rapamycin complex (TORC) 1 signaling had no impact (data not
shown). Thus FGF-2 exerted an anti-apoptotic effect in U2OS
cells that was mediated by ERK1/2 and prevented the cytotoxic
effects of cisplatin. Importantly, upon drug withdrawal, FGF-2-
rescued cells remained viable in culture for several weeks (data not
shown). This further supports the notion that FGF-2 can
effectively promote the survival of cancer cells exposed to cytotoxic
drugs.
In SCLC cells, FGF-2-mediated drug resistance pathways
involves the formation of a protein complex involving PKCe,B -
RAF and S6K2 [4]. We next asked whether FGF-2 could induce
similar protein interactions in U2OS cells. Cells incubated in the
presence or absence of FGF-2 for the times indicated were lyzed
and S6K2 immunoprecipitated prior to western blotting for
PKCe, B-RAF or S6K2 (Fig. 2A). B-RAF and PKCe associated
with S6K2 in resting cells, an effect that was significantly increased
by FGF-2 treatment for 10 min (Fig. 2A). The interactions were
transient and no longer significant by 30 min post-FGF-2
treatment. To substantiate the notion that the three proteins
interacted, we next immunoprecipitated either PKCe (Fig. 2B)o r
B-RAF (Fig. 2C) from cell lysates. We then performed western
blotting to probe for these proteins and S6K2. While B-RAF and
PKCe basal interaction increased 10 min after FGF-2 stimulation
and subsequently persisted, we were unable to detect S6K2 in
these immunoprecipitates (Fig. 2B, 2C and data not shown). This
may be explained by lower expression levels of S6K2 compared to
PKCe and B-RAF in U2OS cells, variation in stoichiometry of the
associations or the formation of multiple, distinct, protein
complexes. Overall the data suggest that FGF-2 promotes
molecular interactions between PKCe, B-RAF and S6K2. In
parallel with all immunoprecipitations, levels of the three proteins
were also analyzed in whole cell extracts (Fig. S3). Interestingly, a
small (1.5 to 1.7-fold) but highly reproducible and statistically
significant increase of S6K2 was detected 10 min after the
addition of FGF-2 whilst levels of PKCe, B-RAF, ERK1/2 and
b-actin (the latter two used as loading controls) were unaffected
(Fig. S3 and also S5). Whether the increase in S6K2 signal is
purely due to an increase in phosphorylation or stabilization of the
protein remains to be determined. Phosphorylation of ERK1/2
was also monitored to ensure the functionality of FGF-2 (Fig. S3).
To further verify that U2OS cells behaved like SCLC in response
to FGF-2 pro-survival signaling we also determined if an increase
in anti-apoptotic proteins could be detected [8]. As predicted,
FGF-2 increased B-cell leukaemia/lymphoma-2 (BCL-2), BCL-2-
like 1 protein (BCL-xL) and X-linked inhibitor of apoptosis protein
(XIAP) expression levels but, in addition, we also observed
induction of another important anti-apoptotic protein, namely
myeloid cell leukemia sequence (MCL) 1, in U2OS cells (Fig. 2D
and data not shown).
Figure 1. FGF-2 protected U2OS osteosarcoma cells from
cisplatin-mediated cell killing. Cells were incubated in serum-free
media overnight. After 4 h pre-treatment with FGF-2 (10 ng/ml), cells
were treated with cisplatin (60 mM) overnight. A. Cell viability was
measured using the WST-1 assay. Values correspond to tetrazolium salt
WST-1 cleaved into colored formazan compounds by mitochondrial
dehydrogenases. Mean6SEM of three independent experiments
performed in triplicate are presented as fold induction relative to
untreated controls. B. Proteins were separated on a 7.5% SDS-PAGE gel
and western blotting analysis performed on total cell lysates (alive and
dead cells) using antibodies against PARP. b-actin was used as a loading
control. A representative western blot and mean6SEM of densitometric
values (cleaved PARP) from three independent experiments are shown.
C. Cells were permeabilized and the DNA stained with propidium
iodide (PI). Cell cycle profiles were assessed by flow cytometry and the
data mined using FlowJo. Mean6SEM of sub-G1 events from three
independent experiments are expressed as fold-change of sub-G1
populations over the untreated control.
doi:10.1371/journal.pone.0019861.g001
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STAT3 or STAT5, inhibits FGF-2-mediated drug resistance
in U2OS cells
Many cancer cell lines used in research have de-regulated JAK/
STAT signaling. This reflects the in vivo situation as the same is
observed in human tumor specimens. Despite their traditional
roles in immune responses JAKs and STATs are being
increasingly recognized as important molecules in cancer biology.
Our preceding data demonstrated that FGF-2 induced interac-
tions between B-RAF, PKCe and S6K2, increased the expression
of key anti-apoptotic molecules and protected U2OS cells from
cisplatin-induced apoptosis. We next asked whether ubiquitously
expressed JAK family members and/or their substrate STATs
were part of this signaling pathway. To address this question, RNA
interference (RNAi) was induced using short interfering (si)
oligonucleotides against JAK1, JAK2, TYK2, STAT1, STAT3
and STAT5A/B. Throughout this study we have used siRNA
pools each comprising four siRNA oligonucleotides directed
against different regions of the same target molecules. All siRNA
pools were validated by deconvolution and western blotting using
antibodies raised against the known target as well as closely related
molecules, as previously described in our laboratory [18].
Silencing efficiency and specificity of pooled siRNAs are shown
in Figure S4. U2OS cells transfected with siRNA were treated
with or without FGF-2 for 4 h and subsequently exposed to
cisplatin (Fig. 3 and 4). Approximately 50% of U2OS cells that
had silenced JAK1 (siJAK), JAK2 (siJAK2) or TYK2 (siTYK2)
treated with cisplatin underwent apoptosis and this could not be
prevented by pre-treating these cells with FGF-2 (Fig. 3).
Apoptosis was assessed using the WST-1 assay (data not shown),
or using PARP cleavage (Fig. 3A) and DNA fragmentation
(Fig. 3B) as readouts. In stark contrast, the increased PARP
cleavage and sub-G1 cell population induced by cisplatin was
prevented by FGF-2 in control cells transfected with a non-specific
siRNA (NS) and in untransfected cells. Thus, each of the analyzed
JAKs was required for efficient FGF-2-mediated chemoprotection
from cisplatin-induced apoptosis.
We next examined whether JAKs might act through their
canonical downstream targets STAT1, STAT3 or STAT5.
However, silencing each of these molecules individually had no
effect on FGF-2-induced drug resistance. Indeed, PARP cleavage
(Fig. 4A) and sub-G1 events (Fig. 4B) triggered by cisplatin
remained significantly reduced in cells pretreated with FGF-2
regardless of the levels of STAT1, STAT3 or STAT5A/B.
FGF-2 induces TYK2 but not STAT phosphorylation
STAT1, STAT3 and STAT5A/B are natural substrates of the
JAKs, but our preceding data indicate that they may not be
required for FGF-2-induced pro-survival signaling. If this were
indeed true, then one would expect FGF-2 to be unable to activate
STATs, a process that involves tyrosine phosphorylation on
specific residues for which phosphospecific antibodies are available
[19]. Consequently, we next investigated whether STATs were
modified downstream of FGF-2 by analyzing tyrosine phosphor-
ylation of STAT1 (Tyr
701), STAT3 (Tyr
705) and STAT5A/B
(Tyr
694) by western blotting. In agreement with our previous
findings (Fig. 4), FGF-2 failed to induce activation of STAT1,
Figure 2. FGF-2 induced interactions between S6K2, PKCe and B-RAF, and upregulation of anti-apoptotic proteins in U2OS cells.
Cells were serum-starved as before and after stimulation with FGF-2 (10 ng/ml), proteins extracted using the co-immunoprecipitation lysis buffer. Cell
lysates were subjected to immunoprecipitation with (A.) S6K2, (B.) PKCe or (C.) B-RAF antibodies and proteins detected by western blotting as
indicated. D. Western blot analysis was performed using total cell lysates and antibodies against MCL1 and BCL-2. b-actin was used as a loading
control. Representative western blots and mean6SEM from three independent experiments are shown in graphs. ‘ – min.
doi:10.1371/journal.pone.0019861.g002
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expected, these proteins could be phosphorylated by Interferon
(IFN)- c, interleukin (IL)-6, or oncostatin M (OSM), which were
used as positive controls (Fig. 5A).
A potential explanation of these findings includes the possibility
that FGF-2 simply fails to activate the JAKs, a process that also
involves tyrosine phosphorylation. To determine whether JAKs
might be activated by FGF-2, we decided to focus our attention on
TYK2, one of the lesser-studied JAKs that is widely expressed in
many cell types. U2OS cells were treated with FGF-2 for different
periods of time and TYK2 was immunoprecipitated. TYK2 tyrosine
phosphorylation was determined using antibodies against phosphor-
ylated tyrosines (4G10 and PY20, 1:1 mix) and TYK2 protein
expression with an anti-TYK2 antibody. FGF-2 induced a transient
2-fold increase in TYK2 tyrosine phosphorylation, which peaked at
5m i na n dr e t u r n e dc l o s et ob a s a ll e v e l sb y3 0m i n( Fig. 5B). No
phospho-TYK2 or TYK2 was seen in control samples (immunopre-
c i p i t a t i o n sw i t hb e a d so n l y ,o rw i t ha ni r r e l e v a n ta n t i b o d y ) .I n
parallel, whole cell lysates used for the immunoprecipitation and
lysatesfromsiTYK2-tranfectedcells(antibodycontrol)wereanalyzed
Figure 3. Knockdown of JAK1, JAK2 or TYK2 blocked the ability
of FGF-2 to prevent cisplatin-induced apoptosis in U2OS cells.
Cells were transfected with 75 nM of siRNA against JAK1, JAK2 or TYK2.
Untransfected cells and cells transfected with non-specific siRNA (NS) were
used as controls. After 48 h, cells were re-plated (2610
5 cells/well) and
incubated in serum-free media overnight. After 4 h pre-treatment with
FGF-2 (10 ng/ml), cells were treated with cisplatin (60 mM) overnight. A.
Mean6SEM of densitometric values (cleaved PARP) from three experi-
ments are shown. B. Cell cycle profiles of three independent experiments
are graphically represented as mean6SEM of sub-G1 populations. The top
panels exemplify the data and correspond to control cells.
doi:10.1371/journal.pone.0019861.g003
Figure 4. Silencing STAT1, STAT3 or STAT5A/B did not impair
the ability of FGF-2 to prevent cisplatin-induced apoptosis in
U2OS cells. Cells were transfected with 75 nM of siRNA against STAT1,
STAT3 or STAT5A/B. Untransfected cells and cells transfected with non-
specific siRNA (NS) were used as controls (c.f. Fig. 3). Cells were treated
as in Figure 3. A. Mean6SEM of densitometric values (cleaved PARP)
from three experiments are shown. B. Cell cycle profiles of three
independent experiments are graphically represented as mean6SEM of
sub-G1 populations.
doi:10.1371/journal.pone.0019861.g004
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potentially activated, downstream of FGF-2. These results together
with those presented in Figure 3 are entirely consistent with a role
for TYK2 downstream of FGF-2 that does not depend on the
simultaneous phosphorylation/activation of STAT1, STAT3 and
STAT5. It remains to be established if JAK1 and JAK2 are also
phosphorylated downstream of FGF-2.
TYK2 binds to PKCe and B-RAF upon FGF-2 treatment
and is required for full phosphorylation of ERK1/2 and
MCL1 induction
The preceding data prompted us to determine if TYK2
interacted with B-RAF, PKCe and S6K2. It was not trivial to
detect TYK2 in S6K2, B-RAF and PKCe protein complex(es)
presumably due to low expression levels for this protein in U2OS
cells. TYK2 was therefore immunoprecipitated after treatment
with FGF-2 and the immunoprecipitates analyzed by western
blotting with antibodies against B-RAF, PKCe and S6K2 instead.
Upon FGF-2 stimulation TYK2 briefly associated with B-RAF
and PKCe (Fig. 6A). The transient nature of these associations
may also explain why it was also difficult to detect S6K2 in these
immunocomplexes. The control lysates are shown in Figure S5.
FGF-2-mediated chemoprotection required ERK1/2 activity
(Fig. S2). To ascertain if this was dependent on TYK2, U2OS
cells were transfected with siTYK2, subsequently treated with
FGF-2 and ERK1/2 phosphorylation assessed by western blot
(Fig. 6B). When compared to untransfected cells, RNAi against
TYK2 significantly reduced ERK1/2 phosphorylation (by 40%
for ERK1 and 25% for ERK2), a phenomenon not observed in
cells transfected with non-specific siRNA. This prompted us to
investigate next whether the upregulation of anti-apoptotic
proteins by FGF-2 was impaired upon TYK2 silencing. RNAi
was performed as before and, as an example, the expression of
MCL1 monitored by western blot (Fig. 6C). Untransfected cells
and cells transfected with either a non-specific siRNA or siERK1/
2 were used as controls. In untransfected cells, or cells transfected
with a non-specific control, FGF-2 lead to a significant increase in
MCL1 protein levels. As predicted, siRNA against ERK1/2
inhibited the upregulation of MCL1 protein. Importantly, MCL1
expression did not increase in response to FGF-2 in cells with
decreased levels of TYK2, suggesting that this JAK is required for
the upregulation of MCL1.
Discussion
There are many molecular mechanisms by which cells can
become resistant to cytotoxic drugs and thus different types of drug
Figure 5. FGF-2 treatment leads to phosphorylation of TYK2,
but not STAT1, STAT3 or STAT5A/B. A. FGF-2 did not induce
STAT1, STAT3, or STAT5 phosphorylation. U2OS cells were serum-
starved overnight and then stimulated with FGF-2 for the indicated
times. Cells treated with IFN-c (500 IU/ml), IL-6 (200 ng/ml)/sIL-6R
(250 ng/ml) and OSM (50 ng/ml) were used as positive controls for
activation of STAT1, STAT3 and STAT5, respectively. Proteins were
analyzed as before using antibodies against phosphorylated STAT1
(Tyr
701), phosphorylated STAT3 (Tyr
705), phosphorylated STAT5 (Tyr
694)
and antibodies that recognize both phosphorylated and unpho-
sphorylated proteins. B. FGF-2 induced the phosphorylation of TYK2
in U2OS cells. Cells were incubated in serum-free media and then
treated with FGF-2 (10 ng/ml) for the indicated times. TYK2 was
immunoprecipitated and western blotting analysis was performed
using antibodies against phosphorylated tyrosines and total TYK2. TYK2
w a su s e da sal o a d i n gc o n t r o l .C. Total cell lysates used to
immunoprecipitate TYK2 and from cells transfected with siTYK2 were
separated on a 7.5% SDS-PAGE gel and analyzed by western blot.
Membranes were probed for TYK2, pERK1/2-Thr
202/185/Tyr
204/187 and
total ERK1/2. b-actin was used as a loading control. ‘ – min.
doi:10.1371/journal.pone.0019861.g005
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been identified as an adverse prognostic factor for many cancer
patients [5,6,7] and Seckl and Pardo have demonstrated its
relevance for drug resistance [3,4,8,9,20].
The output of JAK/STAT signaling pathways impacts far
beyond the cytokine realm. It is widely accepted that JAK/STAT
signaling is highly context-dependent [18,21,22,23,24], that it is
modular in nature and that it involves both cross-talk and cross-
recruitment of other pathways [11,25]. STATs are not usually
found mutated but are frequently seen constitutively activated in
cancer cells [12,19]. In contrast, JAKs are often mutated and thus
de-regulated, particularly in hematological malignancies [26,27].
To our knowledge, JAKs have never been directly implicated in
drug resistance. It is, however, widely recognized that many
cancers are accompanied by inflammation, which is mediated by
cytokines and, consequently, JAK and STAT activity [28]. De-
regulated inflammation, in turn, has been implicated in many
aspects of cancer development and progression, including drug
resistance [12]. Interestingly, JAKs can have contradictory cellular
responses and, as mentioned above, this depends on the trigger
and on the cellular context [13,29]. Proliferative responses can be
directly mediated by the STATs, or by other molecules such as ras
viral oncogene homolog (RAS), ERKs, v-src sarcoma viral
oncogene homolog (SRC) and PI3K [reviewed in [30]]. The
regulation of cytokine responses by the JAKs is STAT-dependent
but JAK-dependent STAT-independent cellular responses have
also been reported. Indeed, JAK1 and JAK2 modulate expression
of BCL-2 family members, molecules crucial for cellular life and
death decisions, independently of STAT activity [31,32]. Studies
using TYK2-deficient cell lines suggested that TYK2 was critical
for the responses to IFN-a/b and some cytokines. In contrast,
knockout mice, despite being more susceptible to viral infections,
had their cytokine responses largely intact [33]. Studies on a
patient with a naturally occurring TYK2 deficiency, however,
suggested that TYK2 was required for full cytokine signaling
[reviewed in [13]]. The precise roles of TYK2, even within
cytokine responses, remain thus to be fully elucidated.
Here, we have shown that in U2OS cells TYK2 is rapidly
phosphorylated downstream of FGF-2 (Fig. 5B), is required for
full activation of ERK1/2 (Fig. 6B) and for the induction of
MCL1 (Fig. 6C). Moreover, TYK2, JAK1 and JAK2 are required
for FGF-2-mediated protection against cisplatin (Fig. 1 and 3).
This effect appears to be independent of the STATs, as silencing of
STAT1, STAT3 or STAT5A/B did not block the survival effects
mediated by FGF-2 (Fig. 1 and 4). Each STAT was silenced
independently and it is possible that concomitant knockdown of all
three STATs, or indeed of other STAT family members, may
impact on FGF-2 drug resistance. The fact that no phosphory-
lation of STATs can be detected following FGF-2 treatment
suggests, however, otherwise (Fig. 5A). It is still not known how
TYK2 is phosphorylated downstream of FGF-2. TYK2 may be
directly recruited to the FGF receptor, or it may be phosphory-
lated further downstream by another kinase such as SRC [30].
The lack of STAT phosphorylation downstream of FGF-2 and
lack of impact on FGF-2 drug resistance (Fig. 4 and 5A) also
suggests that cytokines are not involved in drug resistance
pathways triggered by this growth factor. The role of TYK2 in
FGF-2-mediated drug resistance may be enzymatic and/or
structural (Fig. 5B and 6A). Indeed a structural role for TYK2
has been attributed to TYK2 in IFN-a/b responses where its
presence was not only required for signaling but also for the cell
surface expression of the IFNAR1 chain [34]. Further work is,
therefore, necessary to determine whether TYK2 kinase activity
and/or structure is required to mediate the FGF-2-induced pro-
survival and drug resistance phenotype.
As for SCLC cells [4], treatment of U2OS cells with FGF-2
induces formation of protein complexes involving B-RAF, PKCe and
S6K2 (Fig. 2A–2C). Conceptually, FGF-2 can lead to the formation
of three different dimers (B-RAF/PKCe; B-RAF/S6K2; S6K2/
PKCe)and/ortheformationofatrimer(B-RAF/PKCe/S6K2).The
precise stoichiometry of the protein complexes induced by FGF-2
remains to be determined. The interaction between these three
Figure 6. TYK2 played an important role in FGF-2-mediated
drug resistance. A. FGF-2 induced interaction of TYK2 with PKCe and
B-RAF in U2OS cells. Cells were treated as previously described and
proteins isolated using co-immunoprecipitation buffer. TYK2 was
immunoprecipitated from whole cell lysates and immunoprecipitates
were analyzed using western blots. Membranes were probed for PKCe,
B-RAF and TYK2, the latter used here as a loading control. B. and C.
TYK2 silencing in U2OS cells led to decreased ERK1/2 phosphorylation
and inhibited the upregulation of MCL1 in response to FGF-2. Cells were
transfected with siTYK2 as before. Untransfected cells and cells
transfected with a non-specific siRNA (NS) were used as controls. After
48 h, cells were treated as described previously and then stimulated
with FGF-2 for (B) 10 min and (C)4h .B. Proteins were analyzed using
antibodies against p-ERK1/2 (Thr
202/185/Tyr
204/187) and total ERK1/2.
Values correspond to phospho-ERK1 and -ERK2 levels. C. Western
blotting analysis was performed using total cell lysates and anti-MCL1
antibody. b-actin was used as a loading control and for normalization.
Mean6SEM of densitometric values of three independent experiments
are shown.
doi:10.1371/journal.pone.0019861.g006
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nature, decreasing significantly by 30 min. Although the precise role
of the complex is still being unraveled, it is tempting to speculate that
its function may be to provide a signaling platform where these
kinases can assemble and undergo specific phosphorylation events
required for further downstream biological responses that eventually
lead to cell survival. Interestingly, S6K2 levels quickly increase after
FGF-2 treatment indicating that, in addition to inducing S6K2
phosphorylation, FGF-2 may also stabilize S6K2 (Fig. S3 and S5).
To the best of our knowledge, this is a new finding that warrants a
more detailed investigation. TYK2 immunoprecipitation following
FGF-2 treatment co-immunoprecipitates PKCe and B-RAF, further
suggesting an important role for TYK2 in FGF-2-mediated drug
resistance (Fig. 6A). Accordingly, silencing either TYK2, JAK1 or
JAK2 using RNAi blocked FGF-2 drug resistance against cisplatin
(Fig. 3). It will be particularly pertinent to determine if the formation
of protein complexes involving PKCe, B-RAF and S6K2 depends on
TYK2 since TYK2 phosphorylation is relatively quick and can be
detected 5 min post-FGF-2 treatment. In addition, we have identified
MCL1 as a TYK2-regulated molecule. Indeed, under these
experimental conditions, increased expression of MCL1 following
F G F - 2d e p e n d e do ni n t a c tT Y K 2( Fig. 6C). This is likely an
important finding as, like BCL-2, MCL1 does not induce
proliferation but rather promotes cancer cell viability by blocking
apoptosis [35]. In addition, it is one of the genes highlighted in a study
by Meyerson and co-workers that was designed to identify genomic
areas frequently altered in human cancers [36].
Collectively, our data suggest that TYK2, JAK1 and JAK2 are
novel targets that may prove useful to circumvent drug resistance
mediated by FGF-2, a growth factor often secreted by cancer cells,
or their supporting tissues, and elevated in cancer patients. The
precise molecular mechanisms involved are thus currently under
investigation in our laboratory.
Materials and Methods
Cell culture
U2OS cells from the ATCC were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10% (v/
v) fetal calf serum (FCS) (FirstLink), 2 mM L-glutamine, 50 units/
ml penicillin and 50 mg/ml streptomycin (Biowhittaker) in a
humidified atmosphere of 10% CO2 at 37uC, as previously
described [18]. FGF-2 was from Calbiochem.
Antibodies
Anti-TYK2 (C-20), STAT3 (N-terminal), STAT5A (L-20),
STAT5B (G-2), ERK1 (subdomain XI), B-RAF (H145) and
BCL-2 (100) were purchased from Santa Cruz Biotechnology.
STAT1 (N-terminal) and PY20 antibodies were obtained from BD
Transduction Laboratories. Antibodies against phosphorylated
STAT1 (pSTAT1-Tyr
701), phosphorylated STAT3 (pSTAT3-
Tyr
705), phosphorylated STAT5 (pSTAT5-Tyr
694), phosphorylat-
ed ERK1/2 (pERK1/2-Thr
202/185/Tyr
204/187) and PARP were
bought from Cell Signaling Technology. Anti-MCL1 was from BD
Pharmingen. 4G10 and PKCe antibodies were from Millipore.
The antibody against b-actin was obtained from Sigma-Aldrich.
Anti-S6K2 (430-C-terminus) used for immunoprecipitations was
from Bethyl and the one used for blotting was a gift from Dr I.
Gout (University College London, London, UK).
Protein analysis
Proteins were isolated using Schindler lysis buffer [18] and
concentrations determined using a BioRad assay according to the
manufacturer’s instructions.
Immunoprecipitation
Cells were serum starved overnight [DMEM/0.5% (v/v) FCS],
incubated in DMEM for 2 h and stimulated with FGF-2 (10 ng/
ml) for 5–30 min. After extracting proteins with Schindler’s lysis
buffer, 3 mg were incubated rotating at 4uC for 1 h with 1.6 mg/
ml anti-TYK2, followed by 1 h with protein A-agarose beads.
Immunoprecipitates were washed extensively with lysis buffer and
boiled before separation on a 7.5% SDS-PAGE gel. Co-
immunoprecipitations were done as described previously using
0.3 mg of protein [4]. Importantly, prior to immunoprecipitation
experiments all antibodies were tested for specificity using RNAi
and all experiments have included controls for non-specific protein
binding to the beads. For clarity and conciseness purposes, gels
have been cropped and/or presented in a graphic format. This has
in no way compromised the integrity of the results and all gels are
available for scrutiny.
Drug resistance assays
Cells were starved overnight and then incubated with or without
FGF-2 (10 ng/ml) for 4 h prior to addition of cisplatin. When
carrying out the assay after inducing RNAi, cells were counted and
re-plated. Cell death was measured using WST-1 (Calbiochem), as
directed by the manufacturer. Apoptosis was also assessed by
western blotting and by flow cytometry using PARP cleavage and
DNA fragmentation as readouts, respectively. For the latter, cells
were incubated with propidium iodide (50 mg/ml) and RNase A
(10 mg/ml), cell cycle profiles analyzed and sub-G1 peaks
corresponding to apoptotic cells quantified using FlowJo (Tree
Star, Inc., USA).
RNA interference (RNAi)
This was done as previously described [18].
Statistical analysis
Mean6standard error (SEM) of three independent experiments
were calculated. Student’s t-test was used to determine the
statistical significance of the differences observed between
conditions. A two-tailed p-value below 0.05 was considered
significant. * – p,0.05, ** - p,0.01, *** – p,0.005.
Supporting Information
Figure S1 FGF-2 induced ERK1/2 phosphorylation in
U2OS cells in a dose- and time-dependent manner.
U2OS cells were serum-starved (0.5% FCS) overnight and then
incubated in serum-free media for 1 hour. Cells were stimulated
with FGF-2 for 10 minutes with (A.) the indicated concentrations
or with (B.) 10 ng/ml of FGF-2 for the indicated times. Proteins
were extracted and separated on a 10% SDS-PAGE gel. Western
blotting analysis of total cell lysates was performed using antibodies
against pERK1/2-Thr
202/185/Tyr
204/187 and total ERK1/2. b-
actin was used as a loading control. Representative western blots
and mean6SEM of densitometric values of three independent
experiments are shown in graphs. Values are expressed as fold
change relative to untreated controls. Statistical analysis was
performed using Student’s t-test (* – p,0.05, ** – p,0.01, *** –
p,0.005 versus untreated control). ‘ – min.
(TIF)
Figure S2 FGF-2-mediated drug resistance requires
ERK1/2 phosphorylation. Cells were serum-starved (0.5%
FCS) overnight, incubated in serum-free media for 1 hour and
then pre-treated with 0.5 mM of PD0325901 or with drug vehicle
[0.005% (v/v) DMSO] for 30 minutes. A. Cells were stimulated
JAKs Mediate Drug Resistance Induced by FGF-2
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and separated on a 10% SDS-PAGE gel. Western blotting analysis
was performed on total cell lysates using antibodies against
pERK1/2-Thr
202/185/Tyr
204/187 and total ERK1/2. b-actin was
used as a loading control. B. After 4 hours pre-treatment with
FGF-2, cells were treated with cisplatin (60 mM) overnight,
proteins were extracted from alive and dead cells, run on a
7.5% SDS-PAGE gel and analyzed by western blotting using a
PARP antibody that recognizes cleaved PARP. C. Cells were
treated as in (B.). After 18 h of cisplatin treatment, cells were
harvested, permeabilized and the DNA stained. Apoptosis was
assessed by flow cytometry using loss of DNA content as readout
(% sub-G1 population). Mean6SEM from three independent
experiments are shown in the graphs. Values are expressed as fold
change over untreated controls (without PD0325901 and FGF-2).
Statistical analysis was performed with Student’s t-test (* –
p,0.05, ** – p,0.01, *** – p,0.005 versus untreated control).
[Grey asterisks in (A.): compare the indicated samples].
(TIF)
Figure S3 FGF-2 induced interactions between S6K2,
PKCe and B-RAF. Whole cell lysates used to immunoprecipitate
S6K2, PKCe and B-RAF were separated on a 7.5% SDS-PAGE
gel and analyzed by western blot. Membranes were probed for
PKCe, B-RAF, S6K2, pERK1/2-Thr
202/185/Tyr
204/187 and total
ERK1/2. b-actin was used as a loading control. Representative
western blots and mean6SEM of densitometric values from three
independent experiments are shown in the graph. Values are
expressed as fold change over untreated controls. Statistical
analysis was performed with Student’s t-test (* – p,0.05, *** –
p,0.005 versus untreated controls).
(TIF)
Figure S4 siRNA oligonucleotides can specifically
knockdown TYK2, STAT1, STAT3 and STAT5A/B in
U2OS cells. U2OS cells were transfected with 75 nM siRNA
using DharmaFECT II. After 48 hours, proteins were extracted
and separated on a 7.5% SDS-PAGE gel. Total cell lysates were
western blotted as indicated. Cells were transfected with (A.)
siTYK2, or (B.) with siRNA molecules targeting STAT1, STAT3
or STAT5A/B. Untransfected cells (Unt), or cells transfected with
a non-specific siRNA (NS) were used as controls. Mean6SEM of
densitometric values of three independent experiments are shown
in graphs. Values are expressed as fold change relative to
untransfected controls. Statistical analysis was performed with
Student’s t-test (*** – p,0.005 versus untransfected control). Unt –
untransfected, NS – non-specific siRNA, T2 – TYK2, ST1 –
STAT1, ST3 – STAT3, ST5 – STAT5A/B.
(TIF)
Figure S5 FGF-2 induced interactions between TYK2,
PKCe and B-RAF. Whole cell lysates used to immunoprecipitate
TYK2 were separated on a 7.5% SDS-PAGE gel and analyzed on
a western blot. Membranes were probed for PKCe, B-RAF, S6K2
and TYK2. b-actin was used as a loading control. Representative
western blots and mean6SEM of densitometric values from three
independent experiments are shown in the graph. Values are
expressed as fold change over untreated controls. Statistical
analysis was performed with Student’s t-test (*** – p,0.005 versus
untreated controls).
(TIF)
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